Show simple item record

dc.contributor.authorWells, Paula
dc.contributor.authorWest, Catharine M L
dc.contributor.authorJones, Terry
dc.contributor.authorHarris, Adrian L
dc.contributor.authorPrice, Patricia M
dc.date.accessioned2009-08-19T14:23:53Z
dc.date.available2009-08-19T14:23:53Z
dc.date.issued2004-12-17
dc.identifier.citationMeasuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine. 2004, 1705 (2):91-102 Biochim. Biophys. Actaen
dc.identifier.issn0006-3002
dc.identifier.pmid15588764
dc.identifier.doi10.1016/j.bbcan.2004.09.007
dc.identifier.urihttp://hdl.handle.net/10541/77869
dc.description.abstract[(18)F]-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) is becoming accepted as a diagnostic tool for cancer, but the potential uses of PET in oncology extend beyond the imaging of glucose metabolism. The development of a PET proliferation probe would be a useful pharmacodynamic tool. [(11)C]-thymidine PET has been assessed in man as a specific measure of tumor proliferation. Uptake of [(11)C]-thymidine is related to DNA synthesis and, in human tumors, correlates with proliferation. When compared with (18)F-FDG, it has been shown to be a more sensitive discriminator of early clinical tumor response. 2-[(11)C]-thymidine PET scanning of patients enrolled in early phase clinical trials is feasible and should support future drug development. Although recent research is moving away from the validation of thymidine towards thymidine analogues radiolabeled with (18)F, the better specificity of thymidine for DNA should be the rationale for its continued development and application as a PET probe. This review describes the historical development, application and current research status of [(11)C]-thymidine PET, and aims to highlight the need for its continuing development as a marker of tumor proliferation.
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshCarbon Radioisotopes
dc.subject.meshCell Proliferation
dc.subject.meshClinical Trials as Topic
dc.subject.meshDNA Probes
dc.subject.meshFluorodeoxyglucose F18
dc.subject.meshHumans
dc.subject.meshNeoplasms
dc.subject.meshPositron-Emission Tomography
dc.subject.meshReproducibility of Results
dc.subject.meshThymidine
dc.titleMeasuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine.en
dc.typeArticleen
dc.contributor.departmentDepartment of Radiotherapy, St. Bartholomews' Hospital, West Smithfield, London EC1A 7BE, UK.en
dc.identifier.journalBiochimica et Biophysica Actaen
html.description.abstract[(18)F]-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) is becoming accepted as a diagnostic tool for cancer, but the potential uses of PET in oncology extend beyond the imaging of glucose metabolism. The development of a PET proliferation probe would be a useful pharmacodynamic tool. [(11)C]-thymidine PET has been assessed in man as a specific measure of tumor proliferation. Uptake of [(11)C]-thymidine is related to DNA synthesis and, in human tumors, correlates with proliferation. When compared with (18)F-FDG, it has been shown to be a more sensitive discriminator of early clinical tumor response. 2-[(11)C]-thymidine PET scanning of patients enrolled in early phase clinical trials is feasible and should support future drug development. Although recent research is moving away from the validation of thymidine towards thymidine analogues radiolabeled with (18)F, the better specificity of thymidine for DNA should be the rationale for its continued development and application as a PET probe. This review describes the historical development, application and current research status of [(11)C]-thymidine PET, and aims to highlight the need for its continuing development as a marker of tumor proliferation.


Files in this item

This item appears in the following Collection(s)

Show simple item record